Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasms 2Liver Neoplasms 1Diarrhea 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
shosaiko-to × Clear all
NCT06055179 2025-07-01

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Guangzhou University of Traditional Chinese Medicine

Phase NA Recruiting
98 enrolled
Tumor-Agnostic

Neoplasms

NCT04926545 2024-07-30

XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)

Guangzhou University of Traditional Chinese Medicine

Phase NA Completed
24 enrolled

Diarrhea, Neoplasms

NCT00040898 2013-01-18

Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡